Table 1. Baseline characteristics of the included trials.
| Parameters | Number | Percentage |
|---|---|---|
| Study type | ||
| Interventional | 393 | 97.5 |
| Observational | 10 | 2.5 |
| Phase | ||
| Phase 1 | 72 | 17.9 |
| Phase 1–2 | 53 | 13.2 |
| Phase 2 | 219 | 54.3 |
| Phase 2–3 | 8 | 2.0 |
| Phase 3 | 35 | 8.7 |
| Missing | 16 | 4.0 |
| Sex | ||
| Female | 24 | 6.0 |
| Male | 4 | 1.0 |
| Both | 375 | 93.0 |
| Overall status | ||
| Not yet recruiting | 68 | 16.9 |
| Recruiting | 206 | 51.1 |
| Active, not recruiting | 54 | 13.4 |
| Completed | 26 | 6.5 |
| Terminated | 13 | 3.2 |
| Suspended | 5 | 1.2 |
| Withdrawn | 16 | 4.0 |
| Unknown status | 15 | 3.7 |
| Study results | ||
| Results available | 16 | 4.0 |
| No results available | 387 | 96.0 |
| Sequencing of RT and ICI | ||
| Concomitant | 333 | 82.6 |
| Sequential | 70 | 17.4 |
| Radiation site | ||
| All metastases RT | 2 | 0.5 |
| One metastatic site RT | 4 | 1.0 |
| Multiple sites RT, but not all | 97 | 24.1 |
| Primary tumor RT | 300 | 74.4 |
| Included cohort | ||
| Polymetastatic | 19 | 4.7 |
| Oligometastatic/nonmetastatic | 384 | 95.3 |
RT, radiotherapy; ICI, immune checkpoint inhibitor.